Following earlier reports, BioMarin Pharma (NASDAQ: BMRN) announced that the U.S. Food and Drug Administration (FDA) posted briefing materials prepared ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE